ClinicalTrials.gg
RecruitingNCT07354165VOICE - GIM36Updated Jan 21, 2026

Financial Toxicity in Patients With Early-stage Breast Cancer

An observational study in Breast Cancer, sponsored by National Cancer Institute, Naples. Recruiting at 1 site in Italy. Per ClinicalTrials.gov, last updated 2026-01-21.

Sponsored by National Cancer Institute, Naples · Observational

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
864
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Breast Neoplasms by National Cancer Institute, Naples — 2 open to participants now, 4 under way, 1 of them phase 3. Breast Neoplasms · National Cancer Institute, Naples.

Started
2025
the only one that year
Observational
3 of 11
2 open now
Registered
11th of 11
by date

Among the 11 studies in Breast Neoplasms by National Cancer Institute, Naples, this one is the only one that started in 2025, is one of 3 observational ones, and was the 11th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

2 of the 11 studies in Breast Neoplasms by National Cancer Institute, Naples are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Breast Neoplasms by National Cancer Institute, Naples, or all of them as a file.
02

Study summary

Non-profit, multicenter, prospective, observational study. This study aims to evaluate whether the articulated treatment algorithm that is now possible for early-stage breast cancer patients does produce tangible changes of financial distress over the time and whether the determinants of financial distress change their relative weight over the time.

Read the detailed description

PROFFIT questionnaire is an Italian instrument for evaluating FT in cancer patients in the Italian healthcare context. It includes 16 total items, 7 measuring FT (defining the PROFFIT financial score) and 9 measuring possible determinants of FT. Primary aim of this study is to describe the rate of patients with early breast cancer experiencing financial toxicity (defined as a change of ≥18 points in the PROFFIT-score [items 1-7]) one year after the beginning of the first oncological treatment. In addition, among secondary aims of this study, we aim to verify whether FT is associated with quality of life response , and with disease free survival and overall survival.

03

Conditions studied

  • Breast Cancer

Keywords

  • early breast cancer
  • financial toxicity
  • quality of life
  • PROFFIT questionnaire
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

early-stage breast cancer patients (see cohorts definition)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed form
  • Age > 18 years at the time of study entry
  • confirmed stage I-III invasive breast carcinoma before starting any systemic treatment.

Exclusion criteria

Exclusion Criteria:

  • Stage IV invasive breast carcinoma
  • Major cognitive dysfunction or psychiatric disorders
  • Any previous systemic treatment for the current breast cancer
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
864 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cohort 1

    patients that received surgery without any further anticancer treatment

    Other: Questionnaires

  • Cohort 2

    patients that received surgery followed by adjuvant chemotherapy only

    Other: Questionnaires

  • Cohort 3

    patients that received surgery followed by chemotherapy and endocrine therapy

    Other: Questionnaires

  • Cohort 4

    patients that received surgery followed by endocrine therapy

    Other: Questionnaires

  • Cohort 5

    patients that received neoadjuvant chemotherapy followed by surgery and no further treatment

    Other: Questionnaires

  • Cohort 6

    patients that received neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy

    Other: Questionnaires

  • Cohort 7

    patients that received neoadjuvant chemotherapy followed by surgery and adjuvant endocrine therapy

    Other: Questionnaires

  • Cohort 8

    patients that received neoadjuvant endocrine therapy followed by surgery and adjuvant endocrine therapy

    Other: Questionnaires

Interventions

  • OtherQuestionnaires

    The PROFFIT questionnaire is a PRO instrument composed by 16 items encompassing all the major life domains where FT can be expressed and is formed by two type of items: (1) outcome (items 1-7) and (2) determinants (items 8-16). EORTC QLQ-C30, EORTC QLQ-BR42 and HADS questionnaires are currently used in clinical practice

06

What researchers measure

Primary outcomes

  1. Financial Toxicity at one year

    The rate of patients with early breast cancer experiencing financial toxicity (defined as a change of ≥18 points in the PROFFIT-score \[items 1-7\]) one year after the beginning of the first oncological treatment

    Time frame: baseline visit (before surgery or chemotherapy/endocrine therapy depending on the cohort), at the end of chemotherapy/endocrine therapy (if applicable), after surgery, 6 months after surgery, 1 year after the baseline questionnaires

Secondary outcomes

  1. Changes in PROFFIT scores

    baseline PROFFIT-score and its trajectory at subsequent time points across different cohorts and in the whole study sample. The Patient Reported Outcome for Fighting FInancial Toxicity (PROFFIT) questionnaire is a PRO instrument composed by 16 items encompassing all the major life domains where financial toxicity can be expressed and consist of two type of items: a) outcome (items 1-7) and b) determinants (items 8-16). PROFFIT financial score is defined according to items 1-7 of the PROFFIT questionnaire, range 0-100, 100 indicating maximum financial toxicity.

    Time frame: baseline, at the end of chemotherapy/endocrine therapy (if applicable), after surgery, 6 months after surgery, 1 year after the baseline questionnaires, then every 6 months during endocrine therapy/other treatments/follow-up until 5 yrs from baseline

  2. Financial toxicity "Determinants"

    the individual PROFFIT items (items 8-16 representing potential determinants of financial distress) at baseline and subsequent time points. The Patient Reported Outcome for Fighting FInancial Toxicity (PROFFIT) questionnaire is a PRO instrument composed by 16 items encompassing all the major life domains where financial toxicity can be expressed and consist of two type of items: a) outcome (items 1-7) and b) determinants (items 8-16). PROFFIT financial score is defined according to items 1-7 of the PROFFIT questionnaire, range 0-100, 100 indicating maximum financial toxicity.

    Time frame: baseline, at the end of chemotherapy/endocrine therapy (if applicable), after surgery, 6 months after surgery, 1 year after the baseline questionnaires, then every 6 months during endocrine therapy/other treatments/follow-up until 5 yrs from baseline

  3. PROFFIT score and survival

    the prognostic role of baseline PROFFIT-score in terms of disease-free survival (DFS), as well as overall survival (OS). The Patient Reported Outcome for Fighting FInancial Toxicity (PROFFIT) questionnaire is a PRO instrument composed by 16 items encompassing all the major life domains where financial toxicity can be expressed and consist of two type of items: a) outcome (items 1-7) and b) determinants (items 8-16). PROFFIT financial score is defined according to items 1-7 of the PROFFIT questionnaire, range 0-100, 100 indicating maximum financial toxicity.

    Time frame: baseline, at the end of chemotherapy/endocrine therapy (if applicable), after surgery, 6 months after surgery, 1 year after the baseline questionnaires, then every 6 months during endocrine therapy/other treatments/follow-up until 5 yrs from baseline

  4. Quality of Life (EORTC QLQ-C30, EORTC-BR42)

    The prognostic role of baseline PROFFIT-score in terms of QoL outcomes. The Patient Reported Outcome for Fighting FInancial Toxicity (PROFFIT) questionnaire is a PRO instrument composed by 16 items encompassing all the major life domains where financial toxicity can be expressed and consist of two type of items: a) outcome (items 1-7) and b) determinants (items 8-16). PROFFIT financial score is defined according to items 1-7 of the PROFFIT questionnaire, range 0-100, 100 indicating maximum financial toxicity. EORTC QLQ-C30 scores calculated according to the EORTC QLQ-C30 Scoring Manual; HRQL score calculated by averaging the responses to the items 29 and 30 of the EORTC QLQ-C30; EORTC QLQ-BR42 scores calculated according to the EORTC QLQ-BR42 Scoring Manual.

    Time frame: baseline, at the end of chemotherapy/endocrine therapy (if applicable), after surgery, 6 months after surgery, 1 year after the baseline questionnaires, then every 6 months during endocrine therapy/other treatments/follow-up until 5 yrs from baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Sep 2030, 60 months after the start.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 60 months is close to that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2025
First posted
Jan 21, 2026
StartActual
Sep 30, 2025
Primary completionEst.
Sep 2030
CompletionEst.
Sep 2034
Last update
Jan 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07354165
Responsible party
Sponsor
First posted
Jan 21, 2026
Start date
Sep 30, 2025
Primary completion
Sep 2030 (estimated)
Completion
Sep 2034 (estimated)
Last update
Jan 21, 2026

Study contacts

Maria Lucia Iacovino, MD
Contact
marialucia.iacovino@istitutotumori.na.it
+3908117770692
Maria Carmela Piccirillo, MD
principal investigator · National Cancer Institute, Naples
Martina Pagliuca, MD
principal investigator · Clinical and Translational Oncology, Scuola Superiore Meridionale, Naples

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion